Referring to the strategy developed for BC, the following therapeutic strategies based on the role of AEP in GC can be considered: (i) a combination of medications consisting of signaling pathway inhibitors and AEPI is feasible; (ii) a prodrug activated by AEP can especially target tumors and the surrounding TME; (iii) immunotherapy plus AEPI is also feasible. This evidence concerns the gene LGMN and breast cancer.